Renal denervation in patients with resistant hypertension:
is it still possible to resuscitate?

Czech version

Authors: Miloš Táborský ¹; Marcela Schejbalová ²
Authors‘ workplace: I. interní klinika kardiologická LF UP a FN Olomouc, přednosta prof. MUDr. Miloš Táborský, CSc., FESC, MBA ¹; Kardiologická ambulance, Heart Solution, s. r. o., Praha 5, vedoucí lékař prof. MUDr. Miloš Táborský, CSc., FESC, MBA ²
Published in: Vnitř Lék 2014; 60(12): 1081-1085
Category: 70. birthday prof. MUDr. Michael Aschermann, DrSc., FESC, FACC

Overview

Transcatheter renal denervation (RDN) has been markedly applied and developed in clinical practice in past five years and not only for patients with resistant hypertension. The issue that more than 50% patients with so-called resistant hypertension are in fact patients without adherence to this type of mediation has not been resolved in RDN trials till now. The study Symplicity HTN-3 showed no differences in blood pressure change between the patients with RDN and group of patients after false procedure who continued in their drug therapy. Future of RDN is more than questionable and there is a need to return to animal studies that will verify the real effectiveness of RDN, subsequently, will redefine population of patients indicated for RDN and confirm the applicability of newly developed techniques.

Key words:
renal denervation – renal sympathetic innervation – resistant hypertension

Sources

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988- 2008. JAMA 2010; 303(20): 2043–2050.

2. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012; 125(13): 1594–1956.

3. Gonzalez O, Iriarte G, Rico E. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatorg B Analyt Technol Biomed Life Sci 2010; 878(28): 2685–2692.

4. Page IH, Heuer GJ. The effect of renal denervationon the level of arterial blood pressure and renal function in essential hypertension. J Clin Invest 1935; 14(1): 27–30.

5. Grimson KS, Orgain ES, Anderson B et al. Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy. Ann Surg 1949; 129(6): 850–871.

6. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25(4 Pt 2): 878–882.

7. Masuo K, Lambert GW, Esler MD et al. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res 2010; 33(6): 521–528.

8. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373(9671): 1275–1281.

9. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment resistant hypertension (the SYMPLICITY HTN-2Trial): a randomised controlled trial. Lancet 2010; 376(9756): 1903–1909.

10. Davis MI, Filion KB, Zhangg D et al. Efectiveness of renal denervation therapy for resistent hypertension. A systematic review and meta-analysis. J Am Coll Cardiol 2013; 62(3): 231–241.

11. Bhatt DL, Kandzari DE, O’Neill WW et al. A controlled trial of renal denervation for resistant hypertension. New Engl J Med 2014; 370(15): 1393–1401.

12. Bakris GL, Townsend RR, Liu M et al. SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol 2014; 64(11): 1071–1078.

13. Kandzari DE. Symplicity HTN-3: insights from the subgroup analysis. Paper presented at the EuroPCR 2014 Hot Line Session. May 22, 2014. Paris, France.

14. Bhatt DL, Kandzari DE, O’Neill WW et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370(15): 1393–1401.

15. Toušek P, Widimský J, jr, Rosa J et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study—PRAGUE-15. Cor et Vasa 2014; 36: e235–e239. Dostupné z WWW: <http://www.sciencedirect.com/science/article/pii/S0010865014000435>.

16. Tzafriri AR, Mahfoud F, Keating JH et al. Innervation patterns may limit response to endovascularrenal denervation. J Am Coll Cardiol 2014; 64(11): 1079–1087.

17. Goldschmeding R, Vink A, Weggemans C et al. Limited destruction of renal nerves after catheter based renal denervation: results of a human case study. Nephrol Dial Transplant 2014; 29(8): 1608–1610.

18. Persu A, Jin Y, Baelen M et al. Eligibility for renal denervation. Experience at 11 european expert centers. Hypertension 2014; 63(6): 1319–1325.

19. Václavík J, Sedlák R, Plachý M et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57(6): 1069–1075.